Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Lung Diseases Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

8 recruiting trials for Lung Diseases. Eligibility criteria explained in plain English.

TrialFinderData lists 8 Lung Diseases clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 2 is the largest group at 50% (1 studies); the largest phase groups are Phase 2: 1, Phase 1: 1.

Research is led by Population Health Research Institute (1), Pulmovant, Inc. (1), University of British Columbia (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is inhaled mosliciguat (drug, 1 trial), followed by Dry Powder Inhaler, Trikafta.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
8
Total Trials
8
Recruiting Now
0
Phase 3 Trials
8
Sponsors

Track Lung Diseases trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT03225586

Prospective Urban Rural Epidemiology Study

To examine the impact of health determinants at the individual (e.g. health related behaviors) and societal level (e.g. environmental factors, health related policy, quality of...

Sponsor: Population Health Research InstituteEnrolling: 20000020 locations
RECRUITINGPhase 2NCT07333183

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated...

Sponsor: Pulmovant, Inc.Enrolling: 201 location
RECRUITINGNCT05279040

Trikafta Exercise Study in Cystic Fibrosis

Shortness of breath (dyspnea) during exercise is a major source of distress and is a commonly reported symptom in patients with cystic fibrosis (CF). A recent drug treatment...

Sponsor: University of British ColumbiaEnrolling: 201 location
RECRUITINGPhase 1NCT07552779

A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir

Healthy adults will be enrolled into this open-label, Phase 1 research study. Participants will spend about 9 nights and 10 days in the clinical research unit (CRU) and the total...

Sponsor: PfizerEnrolling: 181 location
RECRUITINGNCT03561818

Comparison of PR Efficiency in Home-based With Hospital-based PR in Bronchiectasis

The investigators aimed to compare the home-based Pulmonary Rehabilitation with the hospital-based pulmonary rehabilitation in terms of pulmonary rehabilitation efficiency in...

Sponsor: Istanbul Medipol University HospitalEnrolling: 501 location
RECRUITINGNCT04664192

Bio-Banking of Specimens for Advanced Lung Disease and Lung Transplant Research

A major goal of this protocol is to support biomarker studies in advanced lung diseases, lung transplantation care, and to improve our understanding of the effects of viral and...

Sponsor: Baylor Research InstituteEnrolling: 1001 location
RECRUITINGNCT05854563

Cough Capture as a Portal Into the Lung

The lung is a privileged organ; blood does not reflect most lung processes well, if at all. Therefore, for population scale diagnostics, the investigator team is developing...

Sponsor: Albert Einstein College of MedicineEnrolling: 20001 location
RECRUITINGNCT04442789

Sequelae of Sars-CoV-2 Infections

By the end of 2019 a new coronavirus, named SARS-CoV-2, was discovered in patients with pneumonia in Wuhan, China. In the following weeks and months the virus spread globally,...

Sponsor: University of GiessenEnrolling: 1201 location

Frequently Asked Questions

There are currently 8 clinical trials for Lung Diseases, with 8 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Lung Diseases, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Lung Diseases, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.